Erratum: Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study (Leukemia (2012) 26 (149-157) DOI: 10.1038/leu.2011.196);Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Leukemia

Volumn 26, Issue 1, 2012, Pages 149-157

  Kumar, S K ^a   Lee, J H ^b   Lahuerta, J J ^c   Morgan, G ^d   Richardson, P G ^e   Crowley, J ^f   Haessler, J ^f   Feather, J ^e   Hoering, A ^f   Moreau, P ^g   Leleu, X ^h   Hulin, C ⁱ   Klein, S K ^j   Sonneveld, P ^j   Siegel, D ^k   Blade J ^l   Goldschmidt, H ^m   Jagannath, S ⁿ   Miguel, J S ^o   Orlowski, R ^p   Palumbo, A ^q   Sezer, O ^r   Rajkumar, S V ^a   Durie, B G M ^s   more..

^a MAYO CLINIC   (United States)

^b Gachon University College of Medicine   (South Korea)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f Fred Hutchinson Cancer Research Center   (United States)

^g HÔTEL DIEU   (France)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITY HOSPITAL OF NANCY   (France)

^j ERASMUS MEDICAL CENTER   (Netherlands)

^k HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^l HOSPITAL CLÍNIC   (Spain)

^m UNIVERSITY OF HEIDELBERG   (Germany)

ⁿ Medical Oncology   (United States)

^o HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^p UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^q UNIVERSITY OF TURIN   (Italy)

^r UNIVERSITY OF HAMBURG   (Germany)

^s CEDARS SINAI MEDICAL CENTER   (United States)

more..

Author keywords

multiple myeloma; natural history; relapse; survival

Indexed keywords

BORTEZOMIB; LENALIDOMIDE; THALIDOMIDE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; EVENT FREE SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84856719479     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.15     Document Type: Erratum

References (31)

1. Rajkumar SV, Blood E, Vesole DH, Fonseca R, Greipp PR. Phase iii clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431-436. (Pubitemid 46630462)
2. Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319-4323. (Pubitemid 35266292)
3. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005; 106: 4050-4053. (Pubitemid 41775908)
4. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498. (Pubitemid 41007864)
5. Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009; 27: 5008-5014.
6. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133-2142. (Pubitemid 350146108)
7. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123-2132. (Pubitemid 350146107)
8. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010; 11: 29-37.
9. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-2520.
10. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008; 111: 2521-2526.
11. Badros A, Burger AM, Philip S, Niesvizky R, Kolla SS, Goloubeva O et al. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res 2009; 15: 5250-5257.
12. Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R et al. Management of newly diagnosed symptomatic multiple myeloma: updated mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines. Mayo Clin Proc 2009; 84: 1095-1110.
13. Kumar SK, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 2004; 79: 867-874. (Pubitemid 38879952)
14. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617. (Pubitemid 36741588)
15. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
16. Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P. Clinically relevant end points and new drug approvals for myeloma. Leukemia 2008; 22: 231-239. (Pubitemid 351250526)
17. Davis S, Wright PW, Schulman SF, Hill LD, Pinkham RD, Johnson LP et al. Participants in prospective, randomized clinical trials for resected non-small cell lung cancer have improved survival compared with nonparticipants in such trials. Cancer 1985; 56: 1710-1718. (Pubitemid 15228526)
18. Karjalainen S, Palva I. Do treatment protocols improve end results? A study of survival of patients with multiple myeloma in Finland. BMJ 1989; 299: 1069-1072. (Pubitemid 19262532)
19. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115-1123. (Pubitemid 28435189)
20. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473. (Pubitemid 44264086)
21. Kumar S, Lacy MQ, Dispenzieri A, Buadi F, Hayman SR, Dingli D et al. Novel Agents for Initial Therapy of Multiple Myeloma: Comparable Results with Continued Initial Therapy and Delayed Transplantation at Relapse Versus Early Transplantation. ASH Ann Meet Abstr 2009; 114: 956.
22. Sood R, Carloss H, Kerr R, Lopez J, Lee M, Druck M et al. Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib. Am J Hematol 2009; 84: 657-660.
23. Conner TM, Doan QD, Walters IB, LeBlanc AL, Beveridge RA. An observational, retrospective analysis of retreatment with bortezomib for multiple myeloma. Clin Lymph Myeloma 2008; 8: 140-145.
24. Warzocha K, Kraj M, Poglod R, Kwasniak B. Bortezomib in multiple myeloma: treatment and retreatment. A single center experience. Acta Pol Pharm 2008; 65: 753-756.
25. Wolf J, Richardson PG, Schuster M, LeBlanc A, Walters IB, Battleman DS. Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series. Clin Adv Hematol Oncol 2008; 6: 755-760.
26. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 1998; 16: 3832-3842.
27. Gertz MA, Kumar S, Lacy MQ, Dispenzieri A, Dingli D, Hayman SR et al. Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction. Blood 2010; 115: 2348-2353.
28. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
29. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009; 23: 2210-2221.
30. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101: 4569-4575. (Pubitemid 36857829)
31. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007; 109: 3489-3495. (Pubitemid 46572539)